The ascension of copyright’s drug initially ignited significant progress in the pharmaceutical sector, generating a image of guaranteed gains. However, funding in companies primarily reliant on flagship drugs like Viagra presents considerable risks. Exclusive rights expiry has caused alternative challenge, reducing market share and potentially di

The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for game-changing treatments and impressive returns is certain, the linked risks are also considerable.